Vaxcyte Inc. has announced the initiation of the OPUS-3 Phase 3 clinical trial evaluating VAX-31, the company's 31-valent pneumococcal conjugate vaccine candidate, in adults previously vaccinated with lower-valency pneumococcal vaccines. The trial will assess the safety, tolerability, and immunogenicity of VAX-31, including its ability to boost serotype-specific immune responses and broaden coverage in this adult population. The OPUS-3 trial is part of Vaxcyte's comprehensive Phase 3 adult clinical program, which also includes the OPUS-1 pivotal noninferiority trial and the OPUS-2 trial evaluating concomitant administration with a seasonal influenza vaccine. Topline data from the OPUS-3 and OPUS-2 trials are expected in the first half of 2027, while results from the OPUS-1 trial are anticipated in the fourth quarter of 2026. No clinical trial results have been presented yet.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9653128-en) on February 11, 2026, and is solely responsible for the information contained therein.